Location History:
- Mountain View, CA (US) (2001)
- San Jose, CA (US) (2001)
Company Filing History:
Years Active: 2001
Title: C Patrick McAtee: Innovator in Hepatitis E Research
Introduction
C Patrick McAtee is a notable inventor based in Mountain View, CA (US). He has made significant contributions to the field of virology, particularly in the development of diagnostic reagents and vaccine compositions for Hepatitis E virus (HEV). With a total of 2 patents, his work has implications for public health and disease prevention.
Latest Patents
McAtee's latest patents focus on Hepatitis E virus antigens and their uses. The patents describe antigens derived from the enterically transmitted non-A/non-B viral hepatitis agent, known as HEV. Specifically, the patents highlight a soluble 62 kDa species of the capsid protein encoded by ORF2, which is immunoreactive with sera from individuals infected with HEV. These antigens can be produced using a baculovirus expression vector and can form virus-like particles (VLPs). The antigens are valuable as diagnostic reagents in methods and kits for determining HEV infection in individuals. Additionally, they are useful in vaccine compositions aimed at preventing HEV infection.
Career Highlights
C Patrick McAtee is associated with Genelabs Technologies, Inc., where he has been instrumental in advancing research related to Hepatitis E. His innovative work has contributed to the understanding and potential treatment of this viral infection.
Collaborations
Some of McAtee's notable coworkers include Thomas R Fuerst and Patrice O Yarbough. Their collaborative efforts have furthered research in the field of virology and diagnostics.
Conclusion
C Patrick McAtee's contributions to Hepatitis E research through his patents and work at Genelabs Technologies, Inc. highlight his role as an important figure in the field of virology. His innovations have the potential to improve diagnostic methods and vaccine development for Hepatitis E, ultimately benefiting public health.